Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.

ABSTRACT:

Objectives

To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).

Methods

This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (n = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (n = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.

Results

The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were asso

SUBMITTER: Chen R 

PROVIDER: S-EPMC10680133 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature